The Canadian Nuclear Safety Commission has amended Ontario Power Generation’s power reactor operating license for Darlington nuclear power plant to authorize the production of the medical radioisotopes lutetium-177 and yttrium-90.

BWX Technologies subsidiary BWXT Medical has agreed to provide Fusion Pharmaceuticals with generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.

BWXT Medical has submitted a new drug application to the U.S. Food and Drug Administration to request approval of its technetium-99m generator for medical imaging. A daughter isotope of molybdenum-99, Tc-99m is used in more than 40 million diagnostic procedures annually. BWXT Medical is a subsidiary of Lynchburg, Va.-based BWX Technologies.